5:43 PM
 | 
Dec 29, 2016
 |  BC Week In Review  |  Company News  |  Deals

Triphase, Celgene deal

Triphase granted Celgene an option to acquire all assets relating to lymphoma candidate TRPH-222 (CD22-4AP). If Celgene exercises its option, it...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >